8-K: Helius Medical Technologies Explores Strategic Alternatives Amid Reimbursement Challenges

Helius Medical Technologies is exploring strategic options, including a potential sale or merger, due to reimbursement challenges with its PoNS device.

Summary

• Helius Medical Technologies has initiated a strategic review process to maximize stockholder value, engaging B. Riley Securities as a financial advisor.
• This decision was prompted by the deferral of a reimbursement payment determination for the PoNS Controller and inadequate pricing for the PoNS Mouthpiece by the Centers for Medicare & Medicaid Services (CMS).
• CMS has set the PoNS Mouthpiece price at $2,963.30, effective January 1, 2025, which Helius believes is too low.
• Helius is disputing the CMS pricing for the PoNS Controller, arguing it was incorrectly mapped to a TENS device code and should be based on recent market pricing.
• The company has requested a meeting with CMS to revisit the PoNS Mouthpiece pricing before the January 1, 2025 effective date.
• The strategic review will consider various options, including acquisition, merger, reverse merger, asset sales, and licensing.
• Helius management hosted a business update call on November 18, 2024, to discuss these developments.

Sentiment

Score: 3

Explanation: The document conveys a negative sentiment due to the company's financial challenges, reimbursement issues, and the exploration of strategic alternatives, which often indicates distress. While the company is actively trying to address these issues, the overall tone is concerning.

Positives

• Helius is actively seeking ways to maximize stockholder value through a strategic review.
• The company is engaging with CMS to address pricing concerns for the PoNS device.
• Helius has successfully presented evidence to the VA and a private payor supporting fair pricing for the PoNS device.
• The company is taking proactive steps to address reimbursement challenges.

Negatives

• The deferral of a reimbursement payment determination for the PoNS Controller and inadequate PoNS Mouthpiece pricing have limited the company's ability to advance operations.
• The CMS pricing determinations are considered by Helius to be based on incomplete information and erroneous assessments.
• The company's market value has been impacted, and its ability to access public markets for financing has been impeded.
• The third review cycle for PoNS Controller pricing and the uncertain timeline has delayed access to PoNS Therapy for qualified MS patients and delayed Helius commercial launch.

Risks

• There is no guarantee that the strategic review process will result in a favorable outcome.
• The company faces uncertainty regarding future CMS determinations and the success of its communications with CMS.
• Helius is dependent on obtaining adequate reimbursement for its PoNS device to achieve commercial success.
• The company faces risks related to capital requirements, funding availability, manufacturing, and supply chain issues.
• There are risks associated with obtaining national Medicare insurance coverage and securing a reimbursement code.
• The company's ability to build internal commercial infrastructure and secure state distribution licenses is also a risk.

Future Outlook

Helius is exploring strategic alternatives to maximize stockholder value, but the outcome is uncertain. The company is also working to address reimbursement challenges with CMS, but there is no guarantee of success. The company's future is dependent on securing adequate reimbursement for its PoNS device and potentially finding a strategic partner or buyer.

Management Comments

• We disagree with the proposed pricing for the PoNS Mouthpiece and are disappointed CMS has once again mapped the Controller pricing to a code for fundamentally different technology, said Dane Andreeff, Helius President and Chief Executive Officer.
• In the face of this challenge our teams response has been impressive as we continue to pursue fair market access for Medicares Multiple Sclerosis (MS) patients with balance and gait deficit.

Industry Context

The announcement reflects the challenges faced by medical device companies in securing adequate reimbursement from government payers like CMS. The company's struggle to obtain fair pricing for its innovative technology highlights the complexities of the healthcare reimbursement landscape and the impact it can have on a company's financial viability and market access.

Comparison to Industry Standards

• The document does not provide specific details on comparable companies or projects, but it does highlight the challenges of obtaining fair reimbursement for novel medical devices.
• The company's struggle with CMS pricing is not unique, as many medical device companies face similar hurdles in navigating the complex reimbursement landscape.
• The company's engagement of B. Riley Securities for strategic alternatives is a common practice for companies facing financial challenges or seeking to maximize shareholder value.

Stakeholder Impact

• Shareholders face uncertainty due to the strategic review process and potential changes in the company's structure.
• Patients with MS may experience delays in accessing PoNS therapy due to reimbursement challenges.
• Employees may be affected by potential restructuring or changes in the company's operations.
• The company's suppliers and creditors may be impacted by the company's financial situation.

Next Steps

• Helius will continue to engage with CMS to address pricing concerns for the PoNS device.
• The company will explore strategic alternatives with the assistance of B. Riley Securities.
• Helius will continue to pursue fair market access for the PoNS device.

Key Dates

Keywords

Helius Medical Technologies, PoNS, neuromodulation, CMS, reimbursement, strategic alternatives, B. Riley Securities, medical device, gait deficit, multiple sclerosis